VistaGen Therapeutics Inc...

NASDAQ: VTGN · Real-Time Price · USD
3.27
0.31 (10.66%)
At close: Aug 15, 2025, 2:36 PM

VistaGen Therapeutics Income Statement

Financials in USD. Fiscal year is April - March.
Fiscal Year FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022 Mar 31, 2021
Revenue
486K 1.06M -227K 1.11M 1.09M
Cost of Revenue
n/a n/a n/a 815.2K n/a
Gross Profit
486K 1.06M -227K 1.11M 1.09M
Operating Income
-55.97M -33.02M -59.27M -47.78M -17.93M
Interest Income
4.56M 3.35M 49K 20K 15K
Pretax Income
-51.41M -29.36M -59.24M -47.76M -17.93M
Net Income
-51.42M -29.36M -59.25M -47.76M -17.93M
Selling & General & Admin
17.08M 14.06M 14.66M 13.25M 7.1M
Research & Development
39.38M 20.02M 44.38M 35.41M 11.93M
Other Expenses
-635K n/a n/a 232K -400
Operating Expenses
55.82M 34.09M 59.04M 48.89M 19.02M
Interest Expense
n/a n/a 23K n/a 13K
Selling & Marketing Expenses
n/a n/a n/a 2.8M n/a
Cost & Expenses
56.46M 34.09M 59.04M 48.89M 19.02M
Income Tax Expense
7K 4K 6K 3.4K 2.6K
Shares Outstanding (Basic)
30.71M 19.35M 6.96M 6.6M 2.87M
Shares Outstanding (Diluted)
30.71M 19.35M 6.96M 6.6M 2.87M
EPS (Basic)
-1.67 -1.52 -8.51 -7.38 -14.74
EPS (Diluted)
-1.67 -1.52 -8.51 -7.38 -14.74
EBITDA
-55.34M -32.45M -58.74M -47.05M -17.44M
EBIT
-55.97M -33.02M -59.27M -47.76M -17.92M
Depreciation & Amortization
635K 568K 532K 711.1K 477.6K